Akari Therapeutcis (AKTX) Receives Orphan Drug Designation for Treatment of Paroxysmal Nocturnal Hemoglobinuria

September 9, 2016 8:43 AM EDT
Get Alerts AKTX Hot Sheet
Trade AKTX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Akari Therapeutcis' (NASDAQ: AKTX) treatment of paroxysmal nocturnal hemoglobinuria received FDA orphan drug designation. The generic name is coversin; rEV675.

Generic Name: coversin; rEV675
Trade Name: N/A
Date Designated: 09/08/2016
Orphan Designation: Treatment of paroxysmal nocturnal hemoglobinuria
Orphan Designation Status: Designated
FDA Orphan Approval Status:Not FDA Approved for Orphan Indication
Marketing Approval Date: N/A
Approved Labeled Indication:
Exclusivity End Date: N/A
Akari Therapeutics Plc
24 West 40th Street
8th Floor
New York, New York 10018

The sponsor address listed is the last reported by the sponsor to OOPD.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment